<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677426</url>
  </required_header>
  <id_info>
    <org_study_id>00146495</org_study_id>
    <nct_id>NCT04677426</nct_id>
  </id_info>
  <brief_title>129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study</brief_title>
  <official_title>129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is a study to test the reliability of Hyperpolarized Xenon MRI (HXe MRI) as a&#xD;
      biomarker in interstitial lung disease. The study is a non-randomized study to evaluate the&#xD;
      test-retest performance of HXe MRI in Idiopathic Pulmonary Fibrosis (IPF) and chronic&#xD;
      Hypersensitivity Pneumonitis (cHP) as a non-invasive biomarker of disease severity and&#xD;
      prognosis. The study will include approximately 15 subjects with IPF, 15 subjects with cHP&#xD;
      and 10 sex and age-matched normal controls performed across 3 sites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RBC:Barrier Ratio</measure>
    <time_frame>RBC:Barrier will be assessed at Baseline and at 6 months.</time_frame>
    <description>RBC:Barrier ratio will be determined using 129 Xenon MRI in 2 successive scans on two separate days 6 months apart. Same-day Repeated measures will be used to assess reliability of RBC:Barrier. Data acquired at 6 months will be correlated with FVC.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Hypersensitivity Pneumonitis</condition>
  <arm_group>
    <arm_group_label>Subjects with Progressive Interstitial Lung Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assess the intra-visit reliability and sensitivity to progression of 129Xe MR imaging measurements using a standardized imaging protocol in subjects with IPF and cHP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized Xe129</intervention_name>
    <description>Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.</description>
    <arm_group_label>Subjects with Progressive Interstitial Lung Disease</arm_group_label>
    <other_name>Xenon</other_name>
    <other_name>HP 129Xe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults &gt; 18 years of age&#xD;
&#xD;
          -  Diagnosis of progressive chronic HP, IPF as determined by MDD discussion (historical&#xD;
             or during screening period) OR normal control (no history of known lung disease, no&#xD;
             abnormal parenchymal or airway findings on CT examination and no values outside of the&#xD;
             normal for FVC, FEV1, TLC, and DLCO.)&#xD;
&#xD;
          -  FVC % Predicted &gt;45%&#xD;
&#xD;
          -  DLCO % Predicted &gt;30%&#xD;
&#xD;
          -  Progressive lung disease as defined by one of the following criteria within 24 months&#xD;
             of screening visit&#xD;
&#xD;
          -  Relative decline in the FVC ≥ 10% of the predicted value&#xD;
&#xD;
          -  Relative decline in the FVC of ≥ 5% - &lt; 10% of the predicted value and worsening of&#xD;
             respiratory symptoms&#xD;
&#xD;
          -  Relative decline in the FVC of ≥ 5% - &lt; 10% of the predicted value and an increased&#xD;
             extent of fibrosis on prior clinical high-resolution CT&#xD;
&#xD;
          -  Worsening of respiratory symptoms and an increased extent of fibrosis on&#xD;
             high-resolution CT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stable FVC over 2-year period as determined by study physician&#xD;
&#xD;
          -  Unstable cardiac condition within 6 months of screening as determined by study&#xD;
             physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter J Niedbalski, PhD</last_name>
    <phone>913-435-5106</phone>
    <email>pniedbalski@kumc.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Alveolitis, Extrinsic Allergic</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

